Jon Faiz Kayyem Acquires 69,686 Shares of Inhibrx, Inc. (NASDAQ:INBX) Stock

Inhibrx, Inc. (NASDAQ:INBX) Director Jon Faiz Kayyem acquired 69,686 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $14.23 per share, with a total value of $991,631.78. Following the transaction, the director now owns 51,093 shares in the company, valued at approximately $727,053.39. This trade represents a -374.80 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Inhibrx Trading Up 0.7 %

Inhibrx stock traded up $0.10 during midday trading on Friday, reaching $14.08. 54,284 shares of the company’s stock were exchanged, compared to its average volume of 138,526. The stock’s 50-day simple moving average is $15.66 and its 200 day simple moving average is $17.34. Inhibrx, Inc. has a 52 week low of $10.80 and a 52 week high of $18.95.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Black Maple Capital Management LP acquired a new stake in shares of Inhibrx during the first quarter worth $555,000. Price T Rowe Associates Inc. MD increased its position in shares of Inhibrx by 8.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company’s stock worth $518,000 after acquiring an additional 1,112 shares in the last quarter. Finally, Alpine Global Management LLC acquired a new stake in shares of Inhibrx in the 1st quarter worth about $1,224,000. 82.46% of the stock is owned by institutional investors and hedge funds.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.